Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

N/ACompletedNCT00240344

AstraZeneca2,650 enrolled

Overview

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Study Type

OBSERVATIONAL

Enrollment

2,650

Conditions

Hypercholesterolemia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High risk patients * High doses of other statins * LDL-C known, starts with Crestor 10 mg * Permission to use patient data by AstraZeneca (AZ)

Locations (75)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

's-Hertogenbosch, Netherlands

Research Site

Alkmaar, Netherlands

Research Site

Almelo, Netherlands

Research Site

Alphen aan den Rijn, Netherlands

Research Site

Amsterdam, Netherlands

Research Site

Apeldoorn, Netherlands

Research Site

Assen, Netherlands

Research Site

Bergen op Zoom, Netherlands

Research Site

Beverwijk, Netherlands

Research Site

Bilthoven, Netherlands

...and 65 more locations